{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:36:00Z","timestamp":1793741760203,"version":"4.6.1"},"reference-count":15,"publisher":"Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,23]]},"DOI":"10.31744\/einstein_journal\/2025rc1460","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T12:50:18Z","timestamp":1761310218000},"source":"Crossref","is-referenced-by-count":1,"title":["Complex diagnosis and management of metastatic esophagogastric junction adenocarcinoma with colonic and meningeal involvement"],"prefix":"10.31744","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6469-2971","authenticated-orcid":false,"given":"Isadora Yasbick","family":"Spricido","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2989-4610","authenticated-orcid":false,"given":"Tom\u00e1s Costa","family":"Bignoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4455-9995","authenticated-orcid":false,"given":"Yuri Greb","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7221-7821","authenticated-orcid":false,"given":"Pedro Henrique Zavarize de","family":"Moraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16942","reference":[{"issue":"3","key":"key20251024125014_B1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"key20251024125014_B2","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3390\/cancers15030685","article-title":"The evolving landscape of leptomeningeal cancer from solid tumors: a systematic review of clinical trials","volume":"15","author":"Marenco-Hillembrand","year":"2023","unstructured":"Marenco-Hillembrand L, Bamimore MA, Rosado-Philippi J, Perdikis B, Abarbanel DN, Quinones-Hinojosa A, et al. The evolving landscape of leptomeningeal cancer from solid tumors: a systematic review of clinical trials. Cancers (Basel). 2023;15(3):685. Review.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"key20251024125014_B3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cncr.30911","article-title":"Leptomeningeal metastasis from systemic cancer: Review and update on management","volume":"124","author":"Wang","year":"2018","unstructured":"Wang N, Bertalan MS, Brastianos PK. Leptomeningeal metastasis from systemic cancer: Review and update on management. Cancer. 2018; 124(1):21-35. Review.","journal-title":"Cancer"},{"issue":"11","key":"key20251024125014_B4","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1002\/cncr.21082","article-title":"Neoplastic meningitis in patients with adenocarcinoma of the gastrointestinal tract","volume":"103","author":"Giglio","year":"2005","unstructured":"Giglio P, Weinberg JS, Forman AD, Wolff R, Groves MD. Neoplastic meningitis in patients with adenocarcinoma of the gastrointestinal tract. Cancer. 2005;103(11):2355-62. Review.","journal-title":"Cancer"},{"key":"key20251024125014_B5","doi-asserted-by":"crossref","first-page":"iv84","DOI":"10.1093\/annonc\/mdx221","article-title":"EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours","volume":"28","author":"Le Rhun","year":"2017","unstructured":"Le Rhun E, Weller M, Brandsma D, Van den Bent M, de Azambuja E, Henriksson R, Boulanger T, Peters S, Watts C, Wick W, Wesseling P, Rud\u00e0 R, Preusser M; EANO Executive Board and ESMO Guidelines Committee. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann Oncol. 2017;28(suppl_4):iv84-iv99.","journal-title":"Ann Oncol"},{"issue":"42","key":"key20251024125014_B6","doi-asserted-by":"crossref","first-page":"73312","DOI":"10.18632\/oncotarget.20272","article-title":"Leptomeningeal disease: current diagnostic and therapeutic strategies","volume":"8","author":"Nayar","year":"2017","unstructured":"Nayar G, Ejikeme T, Chongsathidkiet P, Elsamadicy AA, Blackwell KL, Clarke JM, et al. Leptomeningeal disease: current diagnostic and therapeutic strategies. Oncotarget. 2017;8(42):73312-28. Review.","journal-title":"Oncotarget"},{"key":"key20251024125014_B7","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.4103\/2152-7806.111304","article-title":"Carcinomatous meningitis: Leptomeningeal metastases in solid tumors","volume":"4","author":"Le Rhun","year":"2013","unstructured":"Le Rhun E, Taillibert S, Chamberlain MC. Carcinomatous meningitis: Leptomeningeal metastases in solid tumors. Surg Neurol Int. 2013;4(Suppl 4):S265-88.","journal-title":"Surg Neurol Int"},{"issue":"11","key":"key20251024125014_B8","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0009-9260(99)91181-9","article-title":"Imaging features of leptomeningeal metastases","volume":"54","author":"Collie","year":"1999","unstructured":"Collie DA, Brush JP, Lammie GA, Grant R, Kunkler I, Leonard R, et al. Imaging features of leptomeningeal metastases. Clin Radiol. 1999;54(11):765-71.","journal-title":"Clin Radiol"},{"issue":"10","key":"key20251024125014_B9","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JOP.19.00324","article-title":"In a Patient With Cancer, Not All That Enhances Is Leptomeningeal Carcinomatosis","volume":"15","author":"Sindhu","year":"2019","unstructured":"Sindhu KK, Chang S, Liu J, Bakst RL, Dharmarajan KV. In a Patient With Cancer, Not All That Enhances Is Leptomeningeal Carcinomatosis. J Oncol Pract. 2019;15(10):558-9.","journal-title":"J Oncol Pract"},{"key":"key20251024125014_B10","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000507","article-title":"How we treat patients with leptomeningeal metastases","volume":"4","author":"Le Rhun","year":"2019","unstructured":"Le Rhun E, Preusser M, van den Bent M, Andratschke N, Weller M. How we treat patients with leptomeningeal metastases. ESMO Open. 2019;4(Suppl 2):e000507. Review.","journal-title":"ESMO Open"},{"key":"key20251024125014_B11","volume-title":"Esophageal and esophagogastric junction cancers. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Version 1.2024","author":"National Comprehensive Cancer Network (NCCN)","year":"2025","unstructured":"National Comprehensive Cancer Network (NCCN). Esophageal and esophagogastric junction cancers. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Version 1.2024. Plymouth Meeting, PA: NCCN; 2025 [cited 2025 July 11]. Available from: https:\/\/www.nccn.org\/login?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/esophageal.pdf"},{"issue":"10294","key":"key20251024125014_B12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021; 398(10294):27-40.","journal-title":"Lancet"},{"issue":"10302","key":"key20251024125014_B13","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","unstructured":"Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, Kojima T, Metges JP, Li Z, Kim SB, Cho BC, Mansoor W, Li SH, Sunpaweravong P, Maqueda MA, Goekkurt E, Hara H, Antunes L, Fountzilas C, Tsuji A, Oliden VC, Liu Q, Shah S, Bhagia P, Kato K; KEYNOTE-590 Investigators. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759-71. Erratum in: Lancet. 2021;398(10314):1874.","journal-title":"Lancet"},{"issue":"11","key":"key20251024125014_B14","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","unstructured":"Rha SY, Oh DY, Ya\u00f1ez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fern\u00e1ndez MG, Li J, Lowery MA, \u00c7il T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181-95. Erratum in: Lancet Oncol. 2024;25(12):e626.","journal-title":"Lancet Oncol"},{"key":"key20251024125014_B15","volume-title":"Minist\u00e9rio da Sa\u00fade. Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA). Opdivo\u00ae (Nivolumabe): nova indica\u00e7\u00e3o. Di\u00e1rio Oficial da Uni\u00e3o. 2022 16 de maio","author":"Brasil","year":"2022","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA). Opdivo\u00ae (Nivolumabe): nova indica\u00e7\u00e3o. Di\u00e1rio Oficial da Uni\u00e3o. 2022 16 de maio. Bras\u00edlia (DF): Minist\u00e9rio da Sa\u00fade; 2022 [citado 2025 Jul 11]. Dispon\u00edvel em: https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/medicamentos\/novos-medicamentos-e-indicacoes\/opdivo-r-nivolumabe-nova-indicacao-3"}],"container-title":["einstein (S\u00e3o Paulo)"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T12:50:20Z","timestamp":1761310220000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.einstein.br\/article\/complex-diagnosis-and-management-of-metastatic-esophagogastric-junction-adenocarcinoma-with-colonic-and-meningeal-involvement\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":15,"alternative-id":["10.31744\/einstein_journal\/2025RC1460"],"URL":"https:\/\/doi.org\/10.31744\/einstein_journal\/2025rc1460","relation":{},"ISSN":["1679-4508","2317-6385"],"issn-type":[{"value":"1679-4508","type":"print"},{"value":"2317-6385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"eRC1460"}}